Proceedings from a CME symposium held at the 2020 Genitourinary Cancers Symposium. Featuring perspectives from Dr Toni K Choueiri, Dr Thomas E Hutson, Dr David F McDermott and Prof Thomas Powles. (Video Program)
TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of renal cell carcinoma (RCC).
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
Toni K Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Department of Medical Oncology
Dana-Farber Cancer Institute
Co-Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
The Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Advisory Committee and Consulting Agreements: Alexion Pharmaceuticals, Analysis Group, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Daré Bioscience, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, GlaxoSmithKline, Heron Therapeutics, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Novartis, Peloton Therapeutics Inc, Pfizer Inc, Prometheus Laboratories Inc, Roche Laboratories Inc, Sanofi Genzyme; Contracted Research: Alexion Pharmaceuticals, Analysis Group, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Corvus Pharmaceuticals, Daré Bioscience, Eisai Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Foundation Medicine, Genentech, GlaxoSmithKline, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Novartis, Peloton Therapeutics Inc, Pfizer Inc, Prometheus Laboratories Inc, Roche Laboratories Inc, Sanofi Genzyme, Takeda Oncology, TRACON Pharmaceuticals Inc; Honoraria: Alexion Pharmaceuticals, Analysis Group, Apollo Endosurgery Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Daré Bioscience, Eisai Inc, EMD Serono Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Foundation Medicine, Genentech, GlaxoSmithKline, Heron Therapeutics, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Novartis, Peloton Therapeutics Inc, Pfizer Inc, Prometheus Laboratories Inc, Roche Laboratories Inc, Sanofi Genzyme.
Thomas E Hutson, DO, PharmD
Director, GU Oncology Program
Co-Director, Urologic Cancer Research and Treatment Center
Texas Oncology
Charles A Sammons Cancer Center
Baylor University Medical Center
Professor of Medicine
Texas A&M HSC College of Medicine
Dallas, Texas
Advisory Committee, Consulting Agreements, Contracted Research and Speakers Bureau: Astellas, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, EMD Serono Inc, Genentech, Merck, Novartis, Pfizer Inc.
David F McDermott, MD
Chief, Medical Oncology
Beth Israel Deaconess Medical Center
Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Consulting Agreements: Alkermes, Bristol-Myers Squibb Company, EMD Serono Inc, Lilly, Merck, Pfizer Inc; Contracted Research: Alkermes, Bristol-Myers Squibb Company, Exelixis Inc, Genentech, Merck, Novartis, Pfizer Inc, X4 Pharmaceuticals Inc.
Thomas Powles, MBBS, MRCP, MD
Professor of Genitourinary Oncology
Barts Cancer Institute
Director of Barts Cancer Centre
Queen Mary University of London
London, United Kingdom
Consulting Agreements: Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Seattle Genetics.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Eisai Inc, Exelixis Inc and Merck.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Release date: April 2020
Expiration date: April 2021
(WIFI is recommended for best performance):